Having trouble viewing this email? View in your browser.

23 July 2019

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.


Low-income country membership

ESCMID has put in place new membership fees for members living in low-income countries: the basic ESCMID membership is now offered for 7 EUR per year. With this initiative, ESCMID wishes to further promote science and healthcare in these countries, and actively involve resident infectious disease specialist and clinical microbiologists in the society activities. The list of eligible countries is updated yearly by the World Bank classification, which classifies economies as low-income, lower-middle-income, upper-middle-income or high-income based on gross national income (GNI) per capita. The list is available on the ESCMID website; questions on membership can be addressed to escmidmembership@escmid.org.

Thank you for sharing this information with potentially interested colleagues.

› Read more

ESCMID Executive Committee Election 2019: call for nominations

Dear ESCMID Member,

At the end of 2019 elections will be held among the membership to fill three (out of eight) positions in the ESCMID Executive Committee, two representing clinical microbiology and one infectious diseases. In April 2020 Past-President and Publications Officer Mario Poljak (clinical microbiology position) and Guidelines Officer Evelina Tacconelli (infectious diseases position) will complete their terms on the ESCMID Executive Committee, while ESCMID Treasurer Alexander W. Friedrich will stand for re-election for one clinical microbiology position after completing his first term.

The Nomination Subcommittee would like to encourage you to propose three candidates (two clinical microbiology specialists and one infectious diseases specialist), taking into consideration their professional excellence, leadership and communication skills, and contributions to the activities of ESCMID. Importantly, candidates must have been ESCMID members in good standing for at least the past three years. The term of office will start at the next Assembly of Members (20 April 2020) and will last four years. Candidates nominated in writing by 50 or more members from at least five different countries (with a minimum of five persons per country) will automatically be selected by the Nomination Subcommittee and their names will appear on the ballot. The Nomination Subcommittee may suggest additional candidates to ensure the balance of gender, region and field of activity.

Since no more than one ESCMID Executive Committee member may come from the same country, nominations for candidates from countries of already confirmed ESCMID Executive Committee members cannot be accepted for the next term. These countries are: Italy, Spain, Turkey, France and Switzerland. Additionally, nominees who fail to be elected may not be nominated again for the term immediately following the unsuccessful candidacy.

To nominate a candidate please complete this form and submit it until the deadline 31 August 2019.

We are looking forward to your nominations.
Best regards,

Mario Poljak
Chair of the ESCMID Nomination Subcommittee

› Read more

Alzheimer’s Disease & Infectious Agents: new research grants from IDSA

In order to identify a potential microbial link to Alzheimer's disease, IDSA is offering up to five (5), $100,000 research grants. All application submissions must be narrowly focused on elucidating the possible roles of infectious agents in the causation of Alzheimer's disease. The awards will support innovative research including basic, clinical, and/or non-traditional approaches. International applications are welcome and you do not need to be a member of IDSA to apply! Click here to read more.

› Read more

ESCMID course on developing clinical guidelines: building the ESCMID Guidelines Evidence Review group

ESCMID is strongly committed to increase efforts towards the transparent and rigorous production of guidance documents in the fields of infectious diseases, clinical microbiology and infection control. To this end, we are currently selecting ESCMID members for the Guidelines Evidence Review Group. The ideal candidate is a motivated young professional willing to participate to a dedicated training course (14-16 October 2019, Verona, Italy) and to be available for systematic reviews in future ESCMID guidelines projects. If you are interested in this opportunity, please follow the link to discover more.

› Read more

ESCMID / European Respiratory Society (ERS) membership collaboration

ESCMID offers our colleagues that are ERS members a 15% discount on the price of ESCMID membership (the discount is not applicable on fees for printed journals). Don't miss this opportunity! Click here to find out more.

› Read more

2018 ESCMID Research Grantee’s Publication on “Global burden of melioidosis in 2015: a systematic review and data synthesis.” Is accessible

Emma Birnie, one of our 2018 ESCMID Research Grantee published a great review entitle: "Global burden of melioidosis in 2015: a systematic review and data synthesis." In The Lancet Infection Disease.

Emma Birnie, HS. Virk, J. Savelkoel et al. assessed the global burden of melioidosis, expressed in disability-adjusted life-years (DALYs), for 2015.

They focus on Melioidosis, an infectious disease caused by the environmental bacterium Burkholderia pseudomallei. It is often fatal, with a high prevalence in tropical areas. Clinical presentation can vary from abscess formation to pneumonia and sepsis. The authors performed a systematic review of the peer-reviewed literature for human melioidosis cases between Jan 1, 1990, and Dec 31, 2015. Quantitative data for cases of melioidosis were extracted, including mortality, age, sex, infectious and post-infectious sequelae, antibiotic treatment, and symptom duration. 2888 articles were screened, of which 475 eligible studies containing quantitative data were retained. Pneumonia, intra-abdominal abscess, and sepsis were the most common outcomes. The authors estimate that in 2015, the global burden of melioidosis was 46 million DALYs (UI 32-66) or 843 per 100 000 people (575-1200).

The authors conclude that Melioidosis causes a larger disease burden than many other tropical diseases that are recognised as neglected, and so it should be reconsidered as a major neglected tropical disease.

Read Emma Birnie, et al. article in July 2019 The Lancet Infection Disease and follow the 2018 ESCMID Research grantee academic footprint!

› Read more

Community acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT-scan indication

P. Loubet et al, aimed to create and validate a Community Acquired Pneumonia (CAP) diagnostic algorithm to facilitate diagnosis and guide chest CT-scan indication in patients with CAP suspicion in Emergency Departments (ED).

The authors performed an analysis of CAP suspected patients enrolled in the ESCAPED study who had undergone chest CT-scan and detection of respiratory pathogens through nasopharyngeal PCRs. An adjudication committee assigned the final CAP probability (gold standard). Variables associated with confirmed CAP were used to create weighted CAP diagnostic scores. The authors estimated the score values for which CT scan helped correctly identify CAP, therefore creating a CAP diagnosis algorithm. Algorithms were externally validated in an independent cohort of 200 patients consecutively admitted in a Swiss hospital for CAP suspicion.

Among the 319 patients included, 51% (163/319) were classified as confirmed CAP and 49% (156/319) as excluded CAP. Cough (weight=1), chest pain (1), fever (1), positive Polymerase Chain Reaction (except for rhinovirus) (1), C-Reactive Protein ≥ 50 mg/L (2) and chest X-ray parenchymal infiltrate (2) were associated with CAP. Patients with a score below 3 had a low probability of CAP (17%, 14/84), whereas those above 5 had a high probability (88%, 51/58). The algorithm (score calculation + CT scan in patients with score between 3 and 5) showed sensitivity 73% (95%CI[66-80]), specificity 89% (95%CI[83-94]), positive predictive value (PPV) 88% (95%CI[81-93]), negative predictive value (NPV) 76% (95%CI[69-82]) and AUC 0.81 (95%CI[0.77-0.85]). The algorithm displayed similar performance in the validation cohort (sensitivity 88% (95%CI[81-92]), specificity 72% (95%CI[60-81]), PPV 86% (95%CI[79-91]), NPV 75% (95%CI[63-84]) and AUC 0.80 (95%CI[0.73-0.87])).

Authors concluded that our CAP diagnostic algorithm may help reduce CAP misdiagnosis and optimize the use of chest CT-scan.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.